Neurocrine Biosciences (NBIX) - 21.99% Below 52-Week High: Buy or Wait?

Stock Details

Neurocrine Biosciences Inc (NBIX), a prominent company in the healthcare sector within the drug manufacturers - specialty & generic industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $145.20. Over the past 52 weeks, it has ranged between $122.14 and $186.12. This places the current price at 78.0% of its 52-week high and 18.9% above its 52-week low. Recent trading volume was recorded at 18,679. The 14-day Relative Strength Index (RSI) stands at 70.48, suggesting overbought conditions. The stock is currently trading above its 50-day moving average of $123.74 by 17.34%. Similarly, it is above its 200-day moving average of $121.92 by 19.09%. The MACD histogram is 0.49, indicating bullish momentum (MACD Line: 2.99, Signal Line: 2.50).

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

20.96

Near market average

Forward P/E

14.12

Earnings expected to grow

PEG Ratio

0.28

Potentially undervalued

Price to Book

3.90

EV/EBITDA

15.65

EPS (TTM)

$6.83

Price to Sales

4.31

Beta

0.38

Less volatile than market

Q:How is NBIX valued relative to its earnings and growth?

Neurocrine Biosciences Inc trades at a P/E ratio of 20.96, which is near the market average of approximately 20, suggesting the market views it as fairly valued relative to its earnings. Looking ahead, the forward P/E of 14.12 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 0.28 suggests the stock may be undervalued relative to its growth rate.

Q:What is NBIX's risk profile compared to the market?

With a beta of 0.38, Neurocrine Biosciences Inc is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 3.90 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

20.90%

Operating Margin

22.20%

EBITDA

$913.30M

Return on Equity

22.10%

Return on Assets

11.70%

Revenue Growth (YoY)

39.50%

Earnings Growth (YoY)

31.10%

Q:How profitable and efficient is NBIX's business model?

Neurocrine Biosciences Inc achieves a profit margin of 20.90%, meaning it retains $20.90 from every $100 in revenue after all expenses. This is an impressive margin, indicating strong pricing power and efficient cost management that allows the company to generate substantial profits. The operating margin of 22.20% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 22.10% and ROA at 11.70%, the company generates strong returns on invested capital.

Q:What are NBIX's recent growth trends?

Neurocrine Biosciences Inc's revenue grew by 39.50% year-over-year, representing robust expansion that significantly outpaces typical market growth rates. This strong top-line performance suggests the company is successfully capturing market share or benefiting from favorable industry trends. Earnings increased by 31.10% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against DRUG MANUFACTURERS - SPECIALTY & GENERIC industry averages for proper context.

Company Size & Market

Market Cap

$14.6B

Revenue (TTM)

$3.37B

Revenue/Share (TTM)

$33.66

Shares Outstanding

101.65M

Book Value/Share

$36.35

Asset Type

Common Stock

Q:What is NBIX's market capitalization and position?

Neurocrine Biosciences Inc has a market capitalization of $14.6B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 101.65M shares outstanding, the company's ownership is relatively concentrated. As a participant in the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry, it competes with other firms in this sector.

Q:How does NBIX's price compare to its book value?

Neurocrine Biosciences Inc's book value per share is $36.35, while the current stock price is $145.20, resulting in a price-to-book (P/B) ratio of 3.99. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$207.81

43.12% upside potential

Analyst Recommendations

Strong Buy

Buy

Hold

Sell

Strong Sell

Q:How reliable are analyst predictions for NBIX?

29 analysts cover NBIX with 86% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $207.81 implies 43.1% upside, but targets are often adjusted to follow price moves rather than predict them.

Q:What is the Wall Street consensus on NBIX?

Current analyst recommendations:4 Strong Buy, 21 Buy, 4 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Oct 4, 2026, 02:45 AM

Technical Indicators

RSI (14-day)

70.48

Overbought

50-Day Moving Average

$123.74

17.34% above MA-50

200-Day Moving Average

$121.92

19.09% above MA-200

MACD Line

2.99

MACD Signal

2.50

MACD Histogram

0.49

Bullish

Q:What does NBIX's RSI value tell investors?

The RSI (Relative Strength Index) for NBIX is currently 70.48, indicating the stock is in overbought territory (above 70). This suggests strong recent buying pressure that may be unsustainable. While overbought conditions can persist in strong trends, traders often watch for RSI divergences or a drop below 70 as potential sell signals. Combined with the price being above the 50-day moving average, this confirms bullish conditions.

Q:How should traders interpret NBIX's MACD and moving average crossovers?

MACD analysis shows the MACD line at 2.99 above the signal line at 2.50, with histogram at 0.49. This bullish crossover suggests upward momentum is building. The 50-day MA ($123.74) is above the 200-day MA ($121.92), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently above both MAs, confirming strength.

Indicators last updated: Jul 15, 2025, 12:30 AM

Neurocrine Biosciences Inc (NBIX) Stock